Literature DB >> 22886212

[Retrospective analysis of treatment for severe ovary hyperstimulation syndrome complicated by pleural effusion and ascites].

Fei Gong1, Hui Guo, Yan Shen, Juan Li, Guangxiu Lu, Ge Lin.   

Abstract

OBJECTIVE: To investigate the effectiveness of treatment for severe ovary hyperstimulation syndrome (OHSS) complicated by pleural effusion and ascites after in vitro fertilization preembryo transfer (IVF-ET).
METHODS: One hundred and thirty-two patients with severe OHSS in our hospital (from January 2007 to December 2010) were retrospectively analyzed and the efficacy of three therapeutic methods was compared. Twenty-five patients in group I were treated with low-molecular dextran and albumin, 67 patients in group II were treated with 6% medium molecular-weight hydroxyethyl starch, and 40 patients in group III were treated with active aspiration of pleural effusion and ascites.
RESULTS: All three therapies improved the symptoms of OHSS and various blood biochemical parameters. The duration of hospitalization of group III [(7.4±4.5) d] was significantly less than those of group I [(21.4±9.2) d] or II [(15.6±6.7) d], and the cost of group III [(2656.2±1882.8) Yuan] was also significantly lower than that of group I or II [(11937.6±7989.8) and (5182.7±2991.7) Yuan, respectively].
CONCLUSION: Abdominal B ultrasonography-guided trans-abdominal wall aspiration of pleural effusion and ascites combined with blood volume maintenance is an effective and economical way to treat OHSS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22886212     DOI: 10.3969/j.issn.1672-7347.2012.07.013

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.

Authors:  Jing Zhao; Bin Xu; Xi Huang; Yi Yan; Yanping Li
Journal:  Reprod Health       Date:  2020-11-20       Impact factor: 3.223

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.